New hope for cancer patients: drug may reduce steroid dependency for arthritis side effect
NCT ID NCT06037811
First seen Mar 04, 2026 · Last updated May 20, 2026 · Updated 11 times
Summary
This study tests whether giving adalimumab early can reduce the need for steroids in people who develop inflammatory arthritis as a side effect of immune checkpoint inhibitor cancer therapy. About 30 adults with new arthritis from their cancer treatment will be randomly assigned to receive either adalimumab injections or standard steroid care. The goal is to see if adalimumab can control arthritis symptoms and lower steroid use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLAMMATORY ARTHRITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
St. Joseph's Health Care
RECRUITINGLondon, Ontario, N6A 4V2, Canada
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.